

In re the Application of: Stamm et al

Application No. 09/899,026

Group Art Unit: 1615

Filed: **July 6, 2001** 

Examiner: B. Seidleck

For:

FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIG

BIOAVAILABILITY AND METHOD FOR PREPARING IT

Attorney Docket No: 107664.115US3

**Assistant Commissioner of Patents** 

Washington, DC 20231

## TERMINAL DISCLAIMER

Laboratories Fournier, S.A. certifies that it is the owner of the entire right, title and interest in Application No. 09/899,026, filed July 6, 2001, entitled "FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT" (hereafter the "above-identified application") by virtue of an assignment recorded in the U.S. Patent and Trademark Office on June 17, 1998, at Reel 9260, Frame 0797.

Laboratories Fournier, S.A. certifies that it is the owner of the entire right, title and interest in Application No. 09/572,330, filed May 18, 2000, entitled "FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT," issued as U.S. Patent No. 6,277,405 on August 21, 2001, by virtue of an assignment recorded in the U.S. Patent and Trademark Office on June 17, 1998, at Reel 9260, Frame 0797.

Laboratories Fournier, S.A. certifies that it is the owner of the entire right, title and interest in Application No. 09/005,128, filed January 9, 1998, entitled "FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT," issued as U.S. Patent No. 6,074,670 on June 13, 2000, by virtue of an assignment recorded in the U.S. Patent and Trademark Office on June 17, 1998, at 02/01/2002 RHARMON 00000008 080219 9260, Frame 0797

> Pursuant to 37 C.F.R. § 1.321, Laboratories Fournier, S.A. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,074,670 or U.S. Patent No.

01 FC:148

6,277,405, and hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,074,670 and U.S. Patent No. 6,277,405, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

Laboratories Fournier, S.A. does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent No. 6,074,670 or U.S. Patent No. 6,277,405, in the event that U.S. Patent No. 6,074,670 or U.S. Patent No. 6,277,405 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.32(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Jan 22, 201

By:

Edward D. Grieff, Esq. Registration No. 38,898

Hale and Dorr LLP

1455 Pennsylvania Avenue, N

Washington, DC 20004